NCT00581945 - Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Canakinumab

The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.

DRUG

Placebo

Matching placebo to ACZ885 administered via intravenous infusion.

Trial Locations (11)

14215

Novartis Investigator Site, Buffalo

21224

Novartis Investigator Site, Baltimore

23225

Novartis Investigator Site, Richmond

29303

Novartis Investigator Site, Spartanburg

32405

Novartis Investigator Site, Panama City

48152

Novartis Investigator Site, Livonia

55402

Novartis Investigator Site, Minneapolis

90095

Novartis Investigator Site, Los Angeles

92801

Novartis Investigator Site, Anaheim

300060

Novartis Investigator Site, Marietta

68198-5885

Novartis Investigator Site, Omaha